Chronic rhinosinusitis affects millions of adults, with standard endoscopic sinus surgery offering temporary relief but frustrating recurrence rates that force patients through repeated procedures. A surgical modification targeting the vidian nerve—which controls nasal gland secretions and vascular responses—may dramatically improve long-term outcomes for allergic rhinitis patients.
This propensity-matched analysis of 375 patients compared standard endoscopic sinus surgery alone against the combined approach including vidian neurectomy. The enhanced procedure reduced operative time from 45 to 34 minutes while achieving superior nasal airflow resistance (0.16 versus 0.21 Pa/cm³·s). More significantly, inflammatory markers dropped substantially, with IL-6 levels falling to 11.16 ng/L compared to 12.61 ng/L in standard surgery patients, indicating better control of underlying inflammatory processes.
The vidian nerve, part of the parasympathetic nervous system, drives mucus hypersecretion and vascular congestion characteristic of allergic rhinitis. By severing this neural pathway, surgeons address root physiological mechanisms rather than merely clearing blocked sinuses. This represents a shift from symptom management to pathway interruption—conceptually similar to how bariatric surgery treats diabetes through hormonal mechanisms beyond weight loss.
While promising, this single-center study requires validation across diverse populations and longer follow-up periods. The 12-month recurrence data, though encouraging, may not capture delayed complications or the full durability of neural disruption. For adults facing repeated sinus interventions, however, this neurectomy addition could transform chronic rhinosinusitis from a recurring nuisance into a definitively treatable condition.